Cargando…

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations

TP53 aberrations are found in approximately 10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and are considered early driver events affecting leukemia stem cells. In this study, we compared features of a total of 84 patients with these disorders seen at a tertiar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dutta, Sayantanee, Moritz, Jennifer, Pregartner, Gudrun, Thallinger, Gerhard G., Brandstätter, Ilona, Lind, Karin, Rezania, Simin, Lyssy, Freya, Reinisch, Andreas, Zebisch, Armin, Berghold, Andrea, Wölfler, Albert, Sill, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913568/ https://www.ncbi.nlm.nih.gov/pubmed/35083527 http://dx.doi.org/10.1007/s00277-022-04766-2

Ejemplares similares

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions
por: Müller, Marian, et al.
Publicado: (2019)

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
por: Daga, Shruti, et al.
Publicado: (2019)

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
por: Zebisch, Armin, et al.
Publicado: (2016)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
por: Hatzl, Stefan, et al.
Publicado: (2020)

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing
por: Kashofer, Karl, et al.
Publicado: (2017)

TNFα Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPα
por: Anirudh, Subramanian, et al.
Publicado: (2020)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

BRAF(V600E) promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis
por: Sconocchia, Tommaso, et al.
Publicado: (2023)

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities
por: Foßelteder, Johannes, et al.
Publicado: (2023)

How often are interventions in cluster-randomised controlled trials of complex interventions in general practices effective and reasons for potential shortcomings? Protocol and results of a feasibility project for a systematic review
por: Siebenhofer, Andrea, et al.
Publicado: (2016)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

Low Valine Serum Levels Predict Increased 1-Year Mortality in Acute Heart Failure Patients
por: Klobučar, Iva, et al.
Publicado: (2023)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients
por: Potočnjak, Ines, et al.
Publicado: (2017)

Techniques for detecting chromosomal aberrations in myelodysplastic syndromes
por: Song, Qibin, et al.
Publicado: (2017)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Quantifying the impact on navigation performance in visually impaired: Auditory information loss versus information gain enabled through electronic travel aids
por: Kreilinger, Alex, et al.
Publicado: (2018)

Complications and mortality of cardiovascular emergency admissions during COVID-19 associated restrictive measures
por: Bugger, Heiko, et al.
Publicado: (2020)

Identify latent chromosomal aberrations relevant to myelodysplastic syndromes
por: Song, Qibin, et al.
Publicado: (2017)

Serum concentrations of asymmetric and symmetric dimethylarginine are associated with mortality in acute heart failure patients
por: Potočnjak, Ines, et al.
Publicado: (2018)

Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care – results from the PICANT trial
por: Ulrich, Lisa R., et al.
Publicado: (2019)

Lower Lean Mass Is Associated with Greater Arterial Stiffness in Patients with Lower Extremity Artery Disease
por: Muster, Viktoria, et al.
Publicado: (2021)

Endovascular Thrombolysis in Hypothenar Hammer Syndrome: A Systematic Review
por: Jud, Philipp, et al.
Publicado: (2021)

How do type of preoperative P2Y(12) receptor inhibitor and withdrawal time affect bleeding? Protocol of a systematic review and individual patient data meta-analysis
por: Schoerghuber, Michael, et al.
Publicado: (2022)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Results of a population-based-assessment: we need better communication and more profound patient involvement
por: Sendlhofer, Gerald, et al.
Publicado: (2017)

Aberrant Methylation-Mediated Suppression of APAF1 in Myelodysplastic Syndrome
por: Zaker, Farhad, et al.
Publicado: (2017)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1vg4o7haorvdbgmcu9nrpsu4iv